- Home
- STTK vs ZDGE Comparison
STTK vs ZDGE Comparison
Compare STTK & ZDGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ZDGE
- Stock Information
- Founded
- STTK 2016
- ZDGE 2008
- Country
- STTK United States
- ZDGE United States
- Employees
- STTK N/A
- ZDGE N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ZDGE Computer Software: Prepackaged Software
- Sector
- STTK Health Care
- ZDGE Technology
- Exchange
- STTK Nasdaq
- ZDGE Nasdaq
- Market Cap
- STTK 38.4M
- ZDGE 40.3M
- IPO Year
- STTK 2020
- ZDGE N/A
- Fundamental
- Price
- STTK $0.77
- ZDGE $4.10
- Analyst Decision
- STTK Hold
- ZDGE
- Analyst Count
- STTK 4
- ZDGE 0
- Target Price
- STTK $3.00
- ZDGE N/A
- AVG Volume (30 Days)
- STTK 229.3K
- ZDGE 96.0K
- Earning Date
- STTK 08-04-2025
- ZDGE 06-12-2025
- Dividend Yield
- STTK N/A
- ZDGE N/A
- EPS Growth
- STTK N/A
- ZDGE N/A
- EPS
- STTK N/A
- ZDGE N/A
- Revenue
- STTK $4,606,000.00
- ZDGE $29,511,000.00
- Revenue This Year
- STTK N/A
- ZDGE N/A
- Revenue Next Year
- STTK N/A
- ZDGE $1.07
- P/E Ratio
- STTK N/A
- ZDGE N/A
- Revenue Growth
- STTK 69.65
- ZDGE 1.27
- 52 Week Low
- STTK $0.69
- ZDGE $1.73
- 52 Week High
- STTK $4.51
- ZDGE $4.89
- Technical
- Relative Strength Index (RSI)
- STTK 41.85
- ZDGE 50.34
- Support Level
- STTK $0.73
- ZDGE $3.70
- Resistance Level
- STTK $0.92
- ZDGE $4.89
- Average True Range (ATR)
- STTK 0.07
- ZDGE 0.30
- MACD
- STTK 0.01
- ZDGE -0.08
- Stochastic Oscillator
- STTK 20.80
- ZDGE 33.61
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.